JUL 02, 2019 01:21 PM PDT

Anticholinergic Drugs and Dementia?

WRITTEN BY: Nouran Amin

A link between anticholinergic drug use and cognitive impairment was recently observed from observational studies on randomized clinical trials. Regenstrief Institute research scientists examined whether anticholinergic drugs can lead to dementia and if cholinergic neurotransmission can be improved. Commentary published in JAMA Internal Medicine explains how researchers identify anticholinergic drug use as a potential public health concern and risk factor for dementia.

Anticholinergic-based medicines work by inhibiting the neurotransmitter acetylcholine and used for the treatment of anxiety, depression, and certain types of pain as well as allergies or sleep problems. They are frequently prescribed to older adults.

Learn more about anticholinergic pharmacology:

"Though we learn about potential risk factors through observational studies, the best way to define a causal relationship between anticholinergics and dementia requires a prospective, randomized trial," states lead author, Dr. Noll Campbell. "In conducting such a trial, we can also learn about the risks and benefits of deprescribing medications, including the impact on symptom control, withdrawal or other adverse events, quality of life, and healthcare utilization."

In the commentary, researchers call for the opportunity to understand the cognitive benefit of deprescribing anticholinergics. They identify ideal drug targets for reducing the anticholinergic burden which includes: “(1) high risk of harm, (2) commonly used and (3) existence of an alternative drug to manage the patient's medical condition, if necessary.”

"Clinicians, health policy makers and patients need to understand the benefits and harms of deprescribing anticholinergics," Dr. Campbell added. "The bottom line is that we need as much high-quality evidence to understand risks and benefits of deprescribing a medication as we have to prescribe it. At the same time, we need to be exploring alternative medications which are known not to harm the aging brain and that patients can afford."

Source: Regenstrief.org

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 17, 2019
Drug Discovery
JUL 17, 2019
Efficacy of Nicotine Replacement Therapy
New research evidence, by the Cochrane Review, indicates that a combination of nicotine replacement therapies are most likely to help smokers quit versus j...
JUL 17, 2019
Drug Discovery
JUL 17, 2019
Potential of Statins to Treat Multiple Sclerosis
A widely used therapeutic statin, simvastatin, which is intended to treat cholesterol was found to be medically beneficial for patients with secondary prog...
JUL 17, 2019
Drug Discovery
JUL 17, 2019
Attaching a removable lock to an arthritis drug
A study published in PLOS Biology suggests that attaching a removable lock to an arthritis drug can increase its effectiveness. The study sheds new light o...
JUL 17, 2019
Health & Medicine
JUL 17, 2019
FDA Approves Vyleesi - "The Female Viagra" for Premenopausal Women
Last Friday, the FDA approved a new drug that some are referring to as “the female Viagra.” Vyleesi, the drug’s market name, is injectabl...
JUL 17, 2019
Drug Discovery
JUL 17, 2019
Controlling The Release of Drug Components Using Artificial DNA
Studies carried out at the Technical University of Munich (TUM) can allow nanapoarticles to be released in pre-defined sequence at specified times. Using a...
JUL 17, 2019
Drug Discovery
JUL 17, 2019
Blood Pressure Medication May Increase Risk for Bowel Condition
According to early-stage research, calcium-channel blocker, which is certain type of a blood pressure lowering drug, may increase the risk of a bowel condi...
Loading Comments...